ESC 365 - Is Lp(a) a risk factor for cardiovascular disease and is it worth treating?

ESC Premium Access

Is Lp(a) a risk factor for cardiovascular disease and is it worth treating?

Session: Cardiovascular risk reduction and dyslipidaemia management: current state and future therapies

Topic: Lipids (Epidemiology and Prevention)

Speaker: Professor E. Stroes (Amsterdam, NL)

Sponsored by Cleveland Clinic

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Erik Stroes

Academic Medical Centre, Amsterdam (Netherlands (The))

39 presentations

0 follower

3 more presentations in this session

PCSK9 inhibitors post Fourier: who should be treated and when?

Speaker: Professor S. Nissen (Cleveland, US)

siRNA therapy: the dawn of a new agent in cholesterol lowering?

Speaker: Doctor L. Cho (Cleveland, US)

Current state of knowledge on the mechanism of action of bempedoic acid and its potential for LDL-C lowering and CV risk reduction.

Speaker: Professor S. Nicholls (Melbourne, AU)

Access the full session

Cardiovascular risk reduction and dyslipidaemia management: current state and future therapies

Speakers: Professor E. Stroes, Professor S. Nissen, Doctor L. Cho, Professor S. Nicholls

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources